Vista Pharmaceuticals (Small Cap) Share Target 2024, 2025 To 2039
|
Vista Pharmaceuticals Limited |
|||
|
Price: ₹11.68 | ||
| 52 Week Low: ₹10.43 52 Week High: ₹17.55 |
|||
| Market Capital: 38.96 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Vista Pharmaceuticals Share Price Target For 2024
- 1.1.1: Vista Pharmaceuticals Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Vista Pharmaceuticals Share Price Target For 2025
- 1.2.1: Vista Pharmaceuticals Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Vista Pharmaceuticals Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Vista Pharmaceuticals Financial Performance
- 3.0.1: Is Vista Pharmaceuticals A Good Buy For Long Term?
To predict the Vista Pharmaceuticals's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Vista Pharmaceuticals Share Price Target For 2024
The line chart displays the monthly closing prices of Vista Pharmaceuticals with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Vista Pharmaceuticals shares in 2024, see the table below.
Vista Pharmaceuticals Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 12.14 (+3.93%) | Price Action: Jan 2021 High |
| 2024 Target 2 | 12.0 (+2.73%) | Price Action: Dec 2005 Low |
| 2024 Target 1 | 11.88 (+1.71%) | Price Action: 04 Apr 2024 Low |
| Current Price | 11.68 | Vista Pharmaceuticals's share price as of 26 Dec 2024 |
| Stop Loss 1 | 11.56 (-1.03%) | Price Action: 20 Dec 2024 Low |
| Stop Loss 2 | 11.43 (-2.15%) | Price Action: 14 Nov 2024 Low |
| Stop Loss 3 | 11.31 (-3.17%) | Price Action: 21 Mar 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Vista Pharmaceuticals is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹11.73 serves as the nearest technical reference point.
Historical Returns: 3-month: -11.85% | 6-month: -7.67% | 1-year: -20.38%
Vista Pharmaceuticals Share Price Target For 2025
The line chart displays the monthly closing prices of Vista Pharmaceuticals with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Vista Pharmaceuticals shares in 2025, see the table below.
Vista Pharmaceuticals Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 16.52 (+41.43%) | Fibonacci Extension Level 64.90% |
| 2025 Target 2 | 16.34 (+39.89%) | Price Action: 08 Jan 2024 Low |
| 2025 Target 1 | 16.15 (+38.27%) | Price Action: 08 Sep 2023 Low |
| Current Price | 11.68 | Vista Pharmaceuticals's share price as of 26 Dec 2024 |
| Stop Loss 1 | 9.99 (-14.47%) | Price Action: 09 Aug 2023 High |
| Stop Loss 2 | 9.89 (-15.33%) | Price Action: 02 Aug 2023 High |
| Stop Loss 3 | 9.7 (-16.96%) | Price Action: 14 Jul 2023 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Vista Pharmaceuticals is currently trading near its 52-week low of ₹10.43, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -20.38% | 3-year: +13.18% | 5-year: +17.03%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Vista Pharmaceuticals Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹11.68 | ||
| 2024 | ₹12.67 | +8.47% | ₹12.86 |
| 2025 | ₹13.20 | +4.18% | ₹14.53 |
| 2026 | ₹13.80 | +4.54% | ₹14.90 |
| 2027 | ₹14.54 | +5.36% | ₹15.27 |
| 2028 | ₹15.52 | +6.74% | ₹15.75 |
| 2029 | ₹13.96 | -10.05% | ₹15.64 |
| 2030 | ₹14.52 | +4.01% | ₹16.00 |
| 2031 | ₹15.15 | +4.33% | ₹16.37 |
| 2032 | ₹15.94 | +5.21% | ₹16.74 |
| 2033 | ₹16.98 | +6.52% | ₹17.23 |
| 2034 | ₹15.25 | -10.18% | ₹17.11 |
| 2035 | ₹15.84 | +3.86% | ₹17.47 |
| 2036 | ₹16.50 | +4.16% | ₹17.84 |
| 2037 | ₹17.33 | +5.03% | ₹18.21 |
| 2038 | ₹18.44 | +6.4% | ₹18.72 |
| 2039 | ₹16.44 | -10.84% | ₹18.58 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Vista Pharmaceuticals Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 38.96 Crore | Market valuation of Vista Pharmaceuticals's shares. |
| Revenue (TTM) | 1 Crore | Total revenue generated by Vista Pharmaceuticals over the past twelve months. |
| Net Income (TTM) | -5.66 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | -454.96% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | -218.25% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-50.88% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
0.23 | Company's total debt divided by total shareholder equity. |
| Total Debt | 9.25 Crore | Sum of Vista Pharmaceuticals's current & long-term financial obligations. |
Is Vista Pharmaceuticals A Good Buy For Long Term?
Vista Pharmaceuticals, a small-cap stock with weak financial performance, may not be a suitable long-term investment at this time. Its recent revenue decline, negative profit margin, and high debt raise concerns about its financial stability. While the stock has shown some positive returns in the past year, its long-term performance has been negative, indicating potential risks for investors.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
